Differential responses in relation to ezrin phosphorylation in cells following incubation with the NSC668394 inhibitors have been reported, for instance in cancer states such as myeloid leukaemia cell lines, where different cells treated with the same dose resulted in differential levels of phosphor-ezrin, especially at concentrations below 12.5 μm [79]. Here, EZR is linked to myeloid leukemia.